Frank Cuttitta

Dr. Frank Cuttitta


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2002 in Microscopy Research and Technique
Verified
Journal Article
Closed access
FCFrank Cuttitta
Frank Cuttitta
Ruben PioRuben Pio
Ruben Pio
MGMercedes Garayoa
Mercedes Garayoa
EZEnrique Zudaire
Enrique Zudaire
MJMiguel Julián
Miguel Julián
Alfredo MartínezAlfredo Martínez
Alfredo Martínez

1 December 2009 in Lymphatic Research and Biology
Verified
Journal Article
Open access
CFChangge Fang
Changge Fang
MMMarta Aparicio Miguel
Marta Aparicio Miguel
IAIngalill Avis
Ingalill Avis
Alfredo MartínezAlfredo Martínez
Alfredo Martínez
EZEnrique Zudaire
Enrique Zudaire
FCFrank Cuttitta
Frank Cuttitta
Adrenomedullin (AM) and gastrin releasing peptide (GRP) are neuroendocrine peptides that have been previously implicated as regulators of angiogenesis and lymphangiogenesis. Using an immortalized human dermal microvascular lymphatic endothelial cell line stably transfected with red fluorescent protein (LEC/RFP), we demonstrate the ability of AM and GRP to augment tube formation complexity of this target cell in a dose-dependent manner. Maximum tube density was initiated at 1n M for both peptides, and as concentrations exceeded 10 n M a decrease in tube formation was noted, hence following a classic rise/fall biological response curve. In addition, we show that appropriate small molecule mimetics to neutralizing monoclonal antibodies of AM or GRP, at 1 μ M concentration, can function to either inhibit (antagonist) or enhance (super agonist) peptide-induced tube formation of LEC/RFP. Our small molecule reagents by themselves have no activity, but in the presence of their respective peptides can mediate a positive or negative response, hence the super agonist designation. These compounds represent new regulatory drugs of the lymphatic system with possible patient application in the clinical management of edema and metastatic disease.

23 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
FCFrank Cuttitta
Frank Cuttitta
JGJosune García-Sanmartín
Josune García-Sanmartín
YFYang Feng
Yang Feng
MSMary Elizabeth Sunday
Mary Elizabeth Sunday
YKYoung Kim
Young Kim
Alfredo MartínezAlfredo Martínez
Alfredo Martínez
Background/Objectives: Cripto-1 (CR1) is a plurifunctional embryonic protein required for implantation and re-expressed in the adult during wound repair, inflammation, and tumorigenesis. CR1 and its predicted CR1 pseudogene product Cripto-3/CR3 are highly homologous proteins, and given this physical attribute, commercially available antibodies cannot discriminate between CR1 and CR3. Methods: A series of mouse monoclonal antibodies [MoAbs] were developed with a high-affinity binding that can differentiate human CR1/CR3 proteins and showed no measurable cross-reactivity. Results: Using these reagents, we confirm that CR3 is a bona fide translated protein found in human tumor tissue, cancer cell lysates, and in normal/cancer patient donor sera. We also reveal that CR1 and CR3 compete for binding to signal transduction protein Nodal, glucose-regulated protein 78Da (GRP78), and activin receptor-like kinase 4 (Alk4). Our discriminatory MoAbs provide new reagents to help clarify current CR1/CR3 protein expression vagaries in the Cripto field of study, challenging established CR1 conventions. In addition, our data validate CR3 involvement in human carcinogenesis and cell signaling pathways, with potential clinical relevance in determining cancer patient prognosis and disease severity.